Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Practice Parameter: Treatment of Nonmotor Symptoms of Parkinson Disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:924-931, Zesiewicz,T.A.,et al, 2010
Neuromuscular Symptoms and Elevated Creatine Kinase After Statin Withdrawal
NEJM 362:564-565, Echaniz-Laguna,A.,et al, 2010
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010
Treatment of Refractory Neurosarcoidosis with Infliximab
JNNP 81:241-246, Santos,E., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Effects of a Central Cholinesterase Inhibitor on Reducing Falls in Parkinson Disease
Neurol 75:1263-1269, Chung,K.A.,et al, 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Tricyclic Antidepressants and Headaches: Systematic Review and Meta-Analysis
BMJ 341:c5222, Jackson,J.L.,et al, 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Dabigatran Etexilate - A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity
Thromb Hemost 103:1116-1127, van Ryn,J.,et al, 2010
Personalized Approaches to Clopidogrel Therapy: Are We There Yet?
Stroke 41:2997-3002, Anderson,C.D.,et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
Acute Toxoplasmosis Infection in a Patient with Ankylosing Spondylitis Treated with Adalimumab: A Case Report
Reumatismo 62:283-285, Azevedo V.F., et al, 2010
What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Assessment of Potential Drug Interactions in Patients with Epilepsy: Impact of Age and Sex
Neurol 72:419-425, Gidal,B.E.,et al, 2009
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009
Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009
Donepezil Treatment of Patients with MCI: A 48-Week Randomized, Placebo-Controlled Trial
Neurol 72:1555-1561, Doody,R.S.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009